Drug Type Small molecule drug |
Synonyms Ipragliflozin L-proline/sitagliptin, Sitagliptin/ipragliflozin, Sitagliptin/ipragliflozin L-proline + [4] |
Target |
Mechanism DPP-4 inhibitors(Dipeptidyl peptidase IV inhibitors), SGLT2 inhibitors(Sodium/glucose cotransporter 2 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date JP (23 Mar 2018), |
Regulation- |
Molecular FormulaC16H20F6N5O6P |
InChIKeyGQPYTJVDPQTBQC-KLQYNRQASA-N |
CAS Registry654671-77-9 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Diabetes Mellitus, Type 2 | JP | 23 Mar 2018 |